Bio-Techne Aktie

Bio-Techne OCF-margin

Driftslikviditetsmargin for Bio-Techne (TECH) pr. 22. aug. 2026 er 24,04 %. I foregående år var Driftslikviditetsmargin 23,58 % — en ændring på 1,96 % (højere).

OCF-margin

24,04 %

YoY

1,96%

Senest opdateret:

Driftslikviditetsmargin for Bio-Techne er 2026 24,04 % . Driftslikviditetsmargin for Bio-Techne var 2025 23,58 % . Det falder dermed med 1,96% højere sammenlignet med året før.

Bio-Techne OCF-margin historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

OCF-margin
Date
OCF-margin
1. jan. 2019
25,44 USD
1. jan. 2020
27,78 USD
1. jan. 2021
37,83 USD
1. jan. 2022
29,42 USD
1. jan. 2023
22,38 USD
1. jan. 2024
25,80 USD
1. jan. 2025
23,58 USD
1. jan. 2026
24,04 USD
Bio-Techne OCF-margin historik
ÅROCF-marginYoY
24,04 %+1,96%
23,58 %-8,60%
25,80 %+15,26%
22,38 %-23,93%
29,42 %-22,22%
37,83 %+36,15%
27,78 %+9,22%
25,44 %-4,00%
26,50 %+3,99%
25,48 %-11,62%
28,83 %-6,44%
30,81 %-19,39%
38,23 %
Access this data via the Eulerpool API

Bio-Techne Aktieanalyse

Hvad laver Bio-Techne? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Bio-Techne aktie

Driftslikviditetsmargin for Bio-Techne er 24,04 % i 2026.

Driftslikviditetsmargin for Bio-Techne ændrede sig fra 23,58 % til 24,04 %, hvilket repræsenterer en ændring på 1,96 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Driftslikviditetsmargin Bio-Techne siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

OCF-margin måler den procentdel af omsætningen, der konverteres til driftslikviditet. Det angiver effektiviteten af likviditetsgenerering fra kernedrift.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne Driftslikviditetsmargins Bio-Techne med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

For at evaluere Driftslikviditetsmargins er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for Driftslikviditetsmargin.

Access this data via the Eulerpool API

Marginer — Bio-Techne

Alle nøgletal — Bio-Techne